Works matching IS 03125963 AND DT 2024 AND VI 63 AND IP 3
Results: 11
Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 279, doi. 10.1007/s40262-024-01358-3
- By:
- Publication type:
- Article
Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 367, doi. 10.1007/s40262-024-01353-8
- By:
- Publication type:
- Article
A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 357, doi. 10.1007/s40262-024-01349-4
- By:
- Publication type:
- Article
Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 381, doi. 10.1007/s40262-024-01347-6
- By:
- Publication type:
- Article
Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 343, doi. 10.1007/s40262-023-01326-3
- By:
- Publication type:
- Article
Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 269, doi. 10.1007/s40262-024-01346-7
- By:
- Publication type:
- Article
Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 395, doi. 10.1007/s40262-023-01344-1
- By:
- Publication type:
- Article
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 333, doi. 10.1007/s40262-023-01342-3
- By:
- Publication type:
- Article
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 303, doi. 10.1007/s40262-023-01335-2
- By:
- Publication type:
- Article
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 293, doi. 10.1007/s40262-023-01330-7
- By:
- Publication type:
- Article
Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 317, doi. 10.1007/s40262-023-01345-0
- By:
- Publication type:
- Article